Alterity Therapeutics Ltd. ( (AU:ATH) ) has shared an announcement.
Alterity Therapeutics Limited reported a 6% decrease in revenue from ordinary activities for the half-year ended December 31, 2024, amounting to $111,299. The company also experienced a 10.2% increase in net loss after tax, totaling $7,173,335. The decline in revenue is attributed to lower interest received on the Group’s bank accounts, while the increase in net loss reflects ongoing challenges in its operations. No dividends were declared for the current or previous financial period, and there were no changes in controlled entities during this period.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics Limited, formerly known as Prana Biotechnology Limited, operates in the biotechnology industry. The company focuses on developing therapies to treat neurodegenerative diseases, leveraging its expertise in targeting misfolded proteins that contribute to these conditions.
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $46.18M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com